How Antibodies Help Defend Your Body

Antibodies are Y-shaped proteins made by specialised white blood cells called B cells. At the tips of each antibody are binding regions with a particular shape and chemical character. These regions can attach to a matching part of a virus, bacterium, toxin or other unfamiliar material. The target part is called an antigen.

The match is selective rather than perfectly exclusive. One antibody usually binds strongly to a small set of closely related shapes, while another antibody recognises something different. Your body can produce a vast variety of B cells, each prepared to make a different antibody. Most never meet the target they fit, but the diversity gives the immune system a broad starting library.

Antibodies do not decide whether something is morally suspicious, despite the dramatic language often used about immunity. They respond to molecular patterns. Other immune cells and signals help determine whether a response should grow, calm down or be avoided.

When an antibody attaches to a virus, it may block the part the virus uses to enter a cell. This is called neutralisation. Antibodies can also bind to toxins and stop them reaching their usual targets. In both cases, the antibody reduces harm by getting in the way.

Antibodies can coat the surface of a microbe, making it easier for immune cells to recognise and swallow. Several antibodies may also link particles together, creating clumps that are easier to clear. Some antibody types activate a group of blood proteins called complement, which can damage microbes and attract more immune activity.

The antibody is therefore more like a bright label and a carefully shaped blocker than a tiny soldier with its own sword. Its real strength comes from directing other parts of the immune system towards the correct target.

When a B cell recognises its matching antigen and receives the right supporting signals, it divides. Some of the new cells become plasma cells that release large amounts of antibody. Others become memory B cells that can remain in the body for a long time.

During a later encounter with the same antigen, memory cells can respond more quickly and strongly. This immune memory is one reason many infections are less severe the second time, and it is the basic idea behind vaccination. A vaccine safely introduces an antigen or instructions related to it, giving the immune system practice without requiring the full disease.

Keep the main sequence clear:

• •A B cell recognises a matching antigen.
• •The B cell receives signals and multiplies.
• •Plasma cells release antibodies.
• •Antibodies block or label the target.
• •Memory cells prepare for a faster future response.

Antibodies come in several classes, each suited to a different job. IgM is usually the first to appear in a new infection and forms a large five-unit structure that is good at clumping microbes together. IgG follows and dominates in the blood, and it can cross the placenta, giving a newborn borrowed protection for its first months. IgA is secreted into mucus, tears, saliva and breast milk, guarding the surfaces where microbes try to enter. IgE is present only in small amounts and helps against parasites, but it is also the class behind allergic reactions such as hay fever.

Because antibodies bind such specific shapes, scientists use them as tools. A lateral flow test, such as a home pregnancy test, contains antibodies fixed in a line across a strip. If the target molecule is in the sample, it is captured there together with coloured particles, and a visible line appears. Monoclonal antibodies, produced in the laboratory from a single cloned line of cells so that every molecule is identical, are now used as medicines against some cancers, autoimmune diseases and infections. The precision that guides your immune system also makes them precise tests and treatments.

Your body can produce an enormous variety of antibodies, far more than the number of genes in your DNA. The explanation is a kind of genetic shuffling. The instructions for the binding tips are stored in several sets of gene segments. As each B cell matures, it cuts and joins one segment from each set, and the joins themselves are slightly imprecise, adding extra variety. Every B cell ends up with its own unique combination. The Japanese scientist Susumu Tonegawa received the Nobel Prize in 1987 for showing how this rearrangement works.

The first antibodies made in an infection often bind only moderately well, but they improve. In parts of lymph nodes called germinal centres, activated B cells multiply while their antibody genes mutate at a very high rate. Cells whose mutated antibodies grip the antigen more tightly receive survival signals, while poorer binders tend to die. Over weeks, this selection produces antibodies that bind far more strongly, a process called affinity maturation. It is one reason a booster dose of some vaccines can produce a stronger, better-matched response than the first dose alone.

Antibodies were put to medical use decades before anyone knew what they were. In 1890 Emil von Behring and Kitasato Shibasaburo, working in Berlin, showed that serum from animals that had been immunised against the tetanus or diphtheria toxin could protect other animals when injected. Something in the blood, which they called antitoxin, neutralised the poison. Within a few years horses were being immunised with gradually increasing doses of diphtheria toxin, and their serum was used to treat children with diphtheria. Behring received the first Nobel Prize in Physiology or Medicine in 1901. In modern terms, the antitoxin was a mixture of antibodies.

This is passive immunity: you receive ready-made antibodies instead of producing your own, so protection begins quickly but fades within weeks or months, because no memory cells are created. The same principle is still in use. Antivenoms for snake bites are made by immunising horses or sheep with small, safe doses of venom and purifying the antibodies from their blood. Because these are foreign proteins, the recipient's own immune system can react against them, so doctors watch for allergic reactions and a delayed illness called serum sickness. Reducing that problem was one motive for developing human and humanised antibodies in the laboratory.

Antibodies that cross the placenta usually protect a baby, but in one situation they cause harm. Red blood cells can carry a surface protein called the RhD antigen. A mother who lacks it, described as Rh negative, may carry a baby who has inherited it from the father. Small amounts of the baby's blood can enter her circulation, most often during birth. Her immune system treats the antigen as foreign and produces anti-D antibodies. The first baby is usually unaffected, because the response begins too late, but the mother is now sensitised and has memory cells ready.

In a later pregnancy with another RhD positive baby, her anti-D antibodies, which belong to the IgG class, cross the placenta and attack the baby's red blood cells. This can cause severe anaemia and jaundice, a condition called haemolytic disease of the newborn. The prevention, introduced in the late 1960s, is a clever use of passive immunity. The mother is given injected anti-D antibodies, which clear the baby's cells from her blood before her own immune system can respond and form memory. Ready-made antibodies are used to stop the body making its own, and the treatment has made this once common disease far rarer.

Antibodies defend you by recognising specific antigens, blocking harmful interactions and marking targets for other immune tools. Memory B cells preserve part of that experience, so a later response can begin faster. Follow recognition, binding and memory, and antibody defence becomes a clear system of teamwork.